Effect of mass of 111In-benzyl-EDTA monoclonal antibody on hepatic uptake and processing in mice

G. P. Adams, S. J. DeNardo, S. V. Deshpande, Gerald L Denardo, C. F. Meares, M. J. McCall, A. L. Epstein

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


In patients, the pharmacokinetic behavior of murine monoclonal antibodies has been observed to vary with the amount of antibody administered. It has been suggested that this reflects human recognition of the foreign mouse protein. We have found that the amount of antibody administered also influenced pharmacokinetic behavior when murine monoclonal antibody was administered to mice. p-Isothiocyanatobenzyl-EDTA, a new chelator which forms complexes with 111In that are stable in vivo, was conjugated to Lym-1, a murine anti-Burkitt's lymphoma monoclonal antibody. The pharmacokinetics of two doses (20 and 0.2 μg) of the 111In labeled radiopharmaceutical were studied in non-tumor bearing BALB/c mice. About 20% (0.04 μg) of the 0.2-μg dose, compared with 8% (1.6 μg) of the 20-μg dose, was found in the liver at 48 h after injection. Both doses demonstrated a biological half-life of approximately 120 h. At least 75% of the 111In was excreted by the kidneys, and essentially all 111In in the urine remained chelated by the EDTA portion of p-isothiocyanatobenzyl-EDTA. From these observations of a dose dependent uptake of this radiopharmaceutical by the liver we conclude that there is a recognition phenomenon in mice for this murine monoclonal antibody.

Original languageEnglish (US)
Pages (from-to)1707-1711
Number of pages5
JournalCancer Research
Issue number7
StatePublished - 1989

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Effect of mass of <sup>111</sup>In-benzyl-EDTA monoclonal antibody on hepatic uptake and processing in mice'. Together they form a unique fingerprint.

Cite this